{"entity":{"id":"oncosyne","kind":"company","name":"Oncosyne","aka":["Oncosyne AS"],"tldr":"Oncosyne is a Norwegian company that grows tiny replicas of a patient's tumour in the laboratory and tests drugs on them, to help choose the treatment most likely to work. Its first test, for bowel cancer that has spread, is being checked in a clinical study.","summary":"Oncosyne AS, registered in Oslo and incorporated on 30 November 2020 according to the Norwegian business register (organisation number 926 191 942), was co-founded by Jarle Bruun, its chief executive, and Peter W. Eide, its chief technology officer, both from cancer research at the University of Oslo. Its iCAN platform screens drugs at high content on patient-derived tumoroids, used both as a service for drug developers and as the basis of functional diagnostic tests. Its first test, for metastatic colorectal cancer, is being validated in a clinical performance study, a pancreatic cancer test is in development, and the PROGRESS study with Akershus and Haukeland University Hospitals is testing whether tumoroids predict radiotherapy response in rectal cancer. Its first registered cancer study, NCT07171554, a clinical performance study of its drug sensitivity test in metastatic colorectal cancer at Lorenskog, was posted on ClinicalTrials.gov in September 2025.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://oncosyne.no/"},{"label":"News","url":"https://oncosyne.no/news/"},{"label":"Norwegian business register entry","url":"https://data.brreg.no/enhetsregisteret/api/enheter/926191942"},{"label":"ClinicalTrials.gov: clinical performance study of the drug sensitivity test (NCT07171554)","url":"https://clinicaltrials.gov/study/NCT07171554"}],"tags":[],"related":[],"cancers":["colorectal","pancreatic"],"sections":["diagnostics"],"technologies":["functional-drug-testing","organoids"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The company website does not state a founding year; the incorporation date and address are from the Brønnøysund Register Centre entry for organisation number 926 191 942, read on 29 October 2026. The company says it is raising funds; no round is recorded. The test's clinical performance has not been reported."],"hq":"Oslo","country":"NO","companyType":"diagnostics","website":"https://oncosyne.no/","stage":"startup","investors":[],"funding":[]},"route":"/companies/oncosyne/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"section":[{"id":"diagnostics","kind":"section","name":"Diagnostics & Biomarkers","route":"/fronts/diagnostics/"}],"technology":[{"id":"functional-drug-testing","kind":"technology","name":"Functional (ex vivo) drug testing","route":"/technologies/functional-drug-testing/"},{"id":"organoids","kind":"technology","name":"Patient-derived organoids","route":"/technologies/organoids/"}]}}